USPTO Posts Comments on Genetic Diagnostic Testing

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

[author: Donald Zuhn]

USPTO SealAs part of its efforts to implement the Leahy-Smith America Invents Act, the U.S. Patent and Trademark Office issued a Federal Register notice (77 Fed. Reg. 3748) earlier this year indicating that the Office had begun to collect information on independent second opinion genetic diagnostic testing where patents and exclusive licenses exist that cover primary genetic diagnostic tests (see "USPTO News Briefs," January 26, 2012).  This collection of information was needed in order for the Office to fulfill its obligations under § 27 of the AIA to prepare a report on genetic diagnostic testing for submission to the Committee of the Judiciary for both the Senate and House.

In the first phase of the Office's information gathering process on genetic diagnostic testing, the Office held two public hearings on the matter.  Readers may recall that Patent Docs author Kevin Noonan testified at the first of these hearings in February (see "Patent Docs Author Testifies at Genetic Diagnostic Testing Hearing"; "USPTO Holds First Hearing on 'Second Opinion' Genetic Testing").  In the second phase of this process, the Office asked members of the public to submit written comments on several topics presented in AIA § 27 or any of the additional issues presented in the Office's Federal Register notice.

To provide the public with access to comments that were submitted in response to the Office's request, a webpage on genetic diagnostic testing has been established as part of the Office's AIA implementation site.  The Office has divided the thirty submissions into those from:

• Intellectual property organizations -- includes comments from the American Bar Association (ABA) Section of Science and Technology Law and Section of Intellectual Property Law, American Intellectual Property Law Association (AIPLA), Association of University Technology Managers (AUTM), Intellectual Property Owners Association (IPO), and Pharmaceutical Research and Manufacturers of America (PhRMA).

• Academic and Research Institutions -- includes comments from Duke Institute for Genome Sciences and Policy.

• Companies -- surprisingly includes comments from organizations such as the American Civil Liberties Union (ACLU), American Medical Association (AMA), and Myriad plaintiffs American Society for Clinical Pathology (ASCP), Breast Cancer Action, and College of American Pathologists (CAP), along with those from companies such as Myriad Genetics and Prometheus Laboratories; other commenters include Bio-Reference Laboratories, Cancer Legal Resource Center, Genspace, Knowledge Ecology International, National Society of Genetic Counselors, and joint comments from Roche Molecular Systems and Abbott Laboratories.

• Individuals -- divided into "practitioners" and "others," with the latter including Dr. Wendy Chung, a plaintiff in the Myriad case, and Dr. Luigi Palombi, who spearheaded a campaign against the BRCA gene patents in Australia, which resulted in an Australian Senate Inquiry into gene patents, and six other commenters (James Evans, Sharonmoyee Goswami, Lori Pressman, Pamela Scudder, Rochelle Shoretz, and Brenda Simon), and the former including comments from three practitioners (Christine Gritzmacher, Siu Lo, and Suzannah Sundby).

IPO #2It would be difficult to adequately cover the full range of comments submitted in response to the Office's notice in a single post, so Patent Docs plans to examine a number of the submissions in subsequent posts.  Today, we look at the comments submitted by the IPO.  In its submission, the IPO focuses on the issues raised in Questions 8 and 9 of the Office's notice, which are as follows:

(8) What effect would providing more widespread access to independent second opinion genetic diagnostic tests have on existing owners and license holders of patents that cover genetic diagnostic tests?  How should policy makers consider the relationship of patents, which may cover purified genetic substances, to proprietary data derived from conducting tests, each of which may be useful in both improving high quality and wide access to testing but may also provide important competitive advantages that can drive investments in research and development?

(9) What effects, if any, do patents and exclusive licenses have on genetic diagnostic testing?
    (a) What effects, if any, do patents and exclusive licenses on genetic diagnostic tests have upon the development of new testing procedures?
    (b) What effects, if any, do patents and exclusive licenses on genetic diagnostic tests have upon how new testing procedures are performed?
    (c) What effects, if any, do patents and exclusive licenses on genetic diagnostic tests have upon the interpretation of testing results?
    (d) What effects, if any, do patents and exclusive licenses on genetic diagnostic tests have upon the further improvement of testing procedures?

With respect to Question 8, the IPO contends that "compelling patent owners to grant licenses for the purpose of permitting third parties to provide second opinion genetic diagnostic tests would have a detrimental effect on the U.S. patent system," by "undermin[ing] the incentive created by the patent system to create new tests, as well as to design around existing patents to provide tests that are comparable to existing tests."  In response to Question 9, the IPO states that "exclusive licenses do not materially reduce the availability of second opinion genetic diagnostic tests, as these tests are usually available from the patent owner or another licensed provider."

The IPO notes that the phrase "confirming genetic diagnostic testing activity" in the AIA encompasses a "very narrow category" of activity, namely providing an individual with independent confirmation of results obtained from another test provider’s prior performance of a test on the individual.  According to the IPO, this is not the type of second opinion that most patients seek.  The IPO suggests instead that "most patients who are seeking second opinions are asking for second medical opinions, not for second diagnostic tests performed by a different testing facility," adding that "[t]he existence of patents and exclusive licenses does not impair in any way patients’ access to second medical opinions" (emphasis added).

In addition, the IPO points out that "while labs [that conduct genetic diagnostic testing and utilize genetic diagnostic products] can be affected by the enforcement of patents, it is diagnostic companies that are most directly affected."  The IPO explains that "[i]f a diagnostic company is excluded from offering a genetic diagnostic test, in most cases, hospitals and reference labs can obtain the desired test from another genetic diagnostic company that is not excluded (either the patentee or the licensee)."

The IPO also notes that "[i]t is rare that a single type of test for a single gene provides independent diagnostic capability," adding that "due to evolving case law in the area of biotechnology, patents for these types of diagnostics are increasingly difficult to obtain and are even more difficult to obtain with a broad claim scope."  However, when confronted with these rare situations, the IPO contends that a diagnostic company has many options:  "It can look for alternative markers (which is typically done), license a number of patents needed to make the complete diagnostic, or choose to license and sell a diagnostic that comprises part of the diagnostic solution sought."  In addition to encouraging diagnostic companies to design around a patented test, "[f]orcing those who have not invented to license provides an economic incentive to invent in the first place and rewards the inventor for doing so."  The IPO argues that if such patents are unavailable or required to be licensed on a compulsory basis, "there will be little incentive for diagnostic companies to conduct or sponsor research in these areas."

The IPO concludes its comments by declaring that it would be "a mistake to weaken the patent system in the area of genetic diagnostic testing."

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.